PUBLISHER: KBV Research | PRODUCT CODE: 1410347
PUBLISHER: KBV Research | PRODUCT CODE: 1410347
LAMEA Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report By Cell Type, By Therapy Type, By Country and Growth Forecast, 2023 - 2030
The Latin America, Middle East and Africa Non Hodgkin Lymphoma Therapeutics Market would witness market growth of 11.3% CAGR during the forecast period (2023-2030).
Drugs like ibrutinib and idelalisib are increasingly used in patients with relapsed or refractory NHL, providing alternative treatment options beyond traditional chemotherapy. In cases of relapse or refractory disease, high-dose chemotherapy followed by autologous stem cell transplantation may be considered salvage therapy. This approach aims to eradicate cancer cells and restore normal blood cell production. Along with active cancer-directed therapies, NHL therapeutics include supportive care measures to manage treatment-related side effects. This may include medications to alleviate nausea, prevent infections, and manage hematologic toxicities.
In advanced stages or cases where curative treatment is not feasible, NHL therapeutics, including palliative chemotherapy and symptom-focused interventions, aim to enhance quality of life by alleviating symptoms and improving overall well-being. Genomic and molecular profiling advances have led to the identification of specific genetic alterations and biomarkers associated with NHL. This information is used to guide treatment decisions, allowing for a more targeted and personalized approach. Participation in clinical trials involving novel agents, innovative immunotherapies, and experimental treatment approaches offers patients access to cutting-edge therapies and enhances NHL treatment paradigms.
Advances in understanding the genetic and molecular characteristics of NHL allow for developing targeted therapies in South Africa. Clinical trials investigate drugs targeting pathways or mutations involved in NHL progression in South Africa. Clinical trials involve discovering and validating biomarkers that can help predict treatment response and guide personalized treatment plans for patients with NHL in South Africa. Innovations in healthcare delivery, including telemedicine and remote monitoring, are explored in clinical trials in South Africa. These approaches can improve access to care, especially for patients in remote or underserved areas in South Africa. Therefore, due to these aspects, the market will expand across the LAMEA region in upcoming years.
The Brazil market dominated the LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $301.6 Million by 2030. Argentina market is exhibiting a CAGR of 11.9% during (2023 - 2030). Additionally, The UAE market would experience a CAGR of 11% during (2023 - 2030).
Based on Cell Type, the market is segmented into B-Cell Lymphoma and T-Cell Lymphoma. Based on Therapy Type, the market is segmented into Radiation Therapy, Chemotherapy, Targeted Therapy, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi S.A.
- AbbVie, Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Bristol-Myers Squibb Company
LAMEA Non Hodgkin Lymphoma Therapeutics Market Report Segmentation
By Cell Type
- B-Cell Lymphoma
- T-Cell Lymphoma
By Therapy Type
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Non Hodgkin Lymphoma Therapeutics Market, by Cell Type
- 1.4.2 LAMEA Non Hodgkin Lymphoma Therapeutics Market, by Therapy Type
- 1.4.3 LAMEA Non Hodgkin Lymphoma Therapeutics Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market at a Glance
- 2.1 Key Highlights
Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.1.1 Overview
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Non Hodgkin Lymphoma Therapeutics Market.
Chapter 5. LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 5.1 LAMEA B-Cell Lymphoma Market by Country
- 5.2 LAMEA T-Cell Lymphoma Market by Country
Chapter 6. LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 6.1 LAMEA Radiation Therapy Market by Country
- 6.2 LAMEA Chemotherapy Market by Country
- 6.3 LAMEA Targeted Therapy Market by Country
- 6.4 LAMEA Others Market by Country
Chapter 7. LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country
- 7.1 Brazil Non Hodgkin Lymphoma Therapeutics Market
- 7.1.1 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.1.2 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 7.2 Argentina Non Hodgkin Lymphoma Therapeutics Market
- 7.2.1 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.2.2 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 7.3 UAE Non Hodgkin Lymphoma Therapeutics Market
- 7.3.1 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.3.2 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 7.4 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market
- 7.4.1 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.4.2 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 7.5 South Africa Non Hodgkin Lymphoma Therapeutics Market
- 7.5.1 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.5.2 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 7.6 Nigeria Non Hodgkin Lymphoma Therapeutics Market
- 7.6.1 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.6.2 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
- 7.7 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market
- 7.7.1 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type
- 7.7.2 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type
Chapter 8. Company Profiles
- 8.1 Pfizer, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional & Segmental Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
- 8.1.5.1 Partnerships, Collaborations, and Agreements:
- 8.1.5.2 Product Launches and Product Expansions:
- 8.1.5.3 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
- 8.2 F. Hoffmann-La Roche Ltd.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Segmental and Regional Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
- 8.3 Sanofi S.A.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Partnerships, Collaborations, and Agreements:
- 8.3.6 SWOT Analysis
- 8.4 AbbVie, Inc.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
- 8.4.5.1 Acquisition and Mergers:
- 8.4.6 SWOT Analysis
- 8.5 Novartis AG
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 Recent strategies and developments:
- 8.5.5.1 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
- 8.6 GlaxoSmithKline PLC
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
- 8.6.5.1 Partnerships, Collaborations, and Agreements:
- 8.6.6 SWOT Analysis
- 8.7 Johnson & Johnson (Johnson & Johnson Services, Inc.)
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental &Regional Analysis
- 8.7.4 SWOT Analysis
- 8.8 Takeda Pharmaceutical Company Limited
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 SWOT Analysis
- 8.9 Bayer AG
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 SWOT Analysis
- 8.10. Bristol-Myers Squibb Company
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional Analysis
- 8.10.4 Research & Development Expenses
- 8.10.5 SWOT Analysis
LIST OF TABLES
- TABLE 1 LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 2 LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 3 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 4 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 5 LAMEA B-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
- TABLE 6 LAMEA B-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
- TABLE 7 LAMEA T-Cell Lymphoma Market by Country, 2019 - 2022, USD Million
- TABLE 8 LAMEA T-Cell Lymphoma Market by Country, 2023 - 2030, USD Million
- TABLE 9 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 10 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 11 LAMEA Radiation Therapy Market by Country, 2019 - 2022, USD Million
- TABLE 12 LAMEA Radiation Therapy Market by Country, 2023 - 2030, USD Million
- TABLE 13 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
- TABLE 14 LAMEA Chemotherapy Market by Country, 2023 - 2030, USD Million
- TABLE 15 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
- TABLE 16 LAMEA Targeted Therapy Market by Country, 2023 - 2030, USD Million
- TABLE 17 LAMEA Others Market by Country, 2019 - 2022, USD Million
- TABLE 18 LAMEA Others Market by Country, 2023 - 2030, USD Million
- TABLE 19 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country, 2019 - 2022, USD Million
- TABLE 20 LAMEA Non Hodgkin Lymphoma Therapeutics Market by Country, 2023 - 2030, USD Million
- TABLE 21 Brazil Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 22 Brazil Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 23 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 24 Brazil Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 25 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 26 Brazil Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 27 Argentina Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 28 Argentina Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 29 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 30 Argentina Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 31 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 32 Argentina Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 33 UAE Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 34 UAE Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 35 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 36 UAE Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 37 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 38 UAE Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 39 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 40 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 41 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 42 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 43 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 44 Saudi Arabia Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 45 South Africa Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 46 South Africa Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 47 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 48 South Africa Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 49 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 50 South Africa Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 51 Nigeria Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 52 Nigeria Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 53 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 54 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 55 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 56 Nigeria Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 57 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2019 - 2022, USD Million
- TABLE 58 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market, 2023 - 2030, USD Million
- TABLE 59 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2019 - 2022, USD Million
- TABLE 60 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Cell Type, 2023 - 2030, USD Million
- TABLE 61 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2019 - 2022, USD Million
- TABLE 62 Rest of LAMEA Non Hodgkin Lymphoma Therapeutics Market by Therapy Type, 2023 - 2030, USD Million
- TABLE 63 Key Information - Pfizer, Inc.
- TABLE 64 Key Information - F. Hoffmann-La Roche Ltd.
- TABLE 65 Key Information - Sanofi S.A.
- TABLE 66 Key information - AbbVie, Inc.
- TABLE 67 Key Information - Novartis AG
- TABLE 68 Key Information - GlaxoSmithKline PLC
- TABLE 69 Key Information - Johnson & Johnson
- TABLE 70 Key Information - Takeda Pharmaceutical Company Limited
- TABLE 71 Key Information - Bayer AG
- TABLE 72 Key Information - Bristol-Myers Squibb Company
